Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04551053
Title To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation
Indications

myelofibrosis

Therapies

Parsaclisib + Ruxolitinib

Ruxolitinib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | BEL | AUT


No variant requirements are available.